ARCT — Arcturus Therapeutics Holdings Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1768224 ·
Last close
$12.87
Market Cap
$365.80M
52W High
$24.17
52W Low
$5.50
ADV30
916,499
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 880,000 | — | -25,545,000 | -23,785,000 | 224,310,000 | 191,483,000 | 52,502,000 |
| Mar 2026 | 610,000 | — | -28,931,000 | -26,964,000 | 245,411,000 | 211,375,000 | 54,049,000 |
| Dec 2025 | 3,081,000 | — | -31,307,000 | -29,079,000 | 271,148,000 | 230,909,000 | 57,163,000 |
| Sep 2025 | 14,153,000 | — | -16,512,000 | -13,448,000 | 282,343,000 | 180,360,000 | 57,784,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-72,729,000
Investing CF
$-41,000
Financing CF
$12,929,000
CapEx
$-318,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.31
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-565,339,000
Inventory
—
Receivables
$1,813,000
ST Investments
—
EBIT TTM
$-91,809,000
Pretax Income TTM
$-93,280,000
Interest Exp TTM
$0
Analysts
10
Yahoo Snapshot (yfinance, live)
Total Revenue
$29,368,000
EBITDA
$-99,548,000
Free Cash Flow
$19,258,624
Enterprise Value
$250,121,808
Total Cash
$191,483,008
Total Debt
$22,933,000
Shares Out
28,423,069
Trailing EPS
$-3.33
Book Value
$6.04
ROE
-46.3%
ROA
-24.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 67,221,000 | -76,260,000 | -65,783,000 | 271,148,000 | 57,163,000 | 213,985,000 | -74,271,000 |
| Dec 2024 | 138,389,000 | -95,669,000 | -80,941,000 | 344,069,000 | 103,091,000 | 240,978,000 | -59,747,000 |
| Dec 2023 | 157,748,000 | -78,205,000 | -29,725,000 | 429,402,000 | 150,889,000 | 278,513,000 | -18,099,000 |
| Dec 2022 | 205,755,000 | 12,177,000 | 9,349,000 | 450,387,000 | 180,075,000 | 270,312,000 | 31,993,000 |
TTM Snapshot
Revenues TTM
$54,710,000
NetIncome TTM
$-78,671,000
OpCashFlow TTM
—
Assets (Latest)
$245,411,000
Forward EPS
$-3.61
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $12.50 · spot: $12.87 · call volume: 33 · put volume: 501
Expected Move to 2026-12-18:
±$3.69
(28.67%) —
implied range
$9.18 –
$16.56
· ATM straddle on $12.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GALT | GALECTIN THERAPEUTICS INC | $367.09M | $3.64 | — |
| PTCHF | PureTech Health plc | $370.22M | $1.51 | — |
| IRD | Opus Genetics, Inc. | $371.05M | $4.46 | — |
| ENTA | ENANTA PHARMACEUTICALS INC | $352.42M | $12.10 | — |
| EBS | Emergent BioSolutions Inc. | $349.17M | $6.81 | — |
News headlines (Yahoo Finance, 1h cache)
Arcturus Highlights ARCT-810 Phase II Data, Unveils Next-Gen OTC Therapy Platform
2026-09-25 03:02 · Yahoo
Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform
2026-09-23 20:01 · Yahoo
Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform
2026-09-18 13:00 · Yahoo
Arcturus Therapeutics to Participate in Upcoming Investor Conferences
2026-08-31 20:01 · Yahoo
Arcturus Therapeutics (ARCT) Just Flashed Golden Cross Signal: Do You Buy?
2026-08-27 13:55 · Yahoo
Arcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds Pipeline
2026-08-12 01:04 · Yahoo
Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference
2026-07-20 20:01 · Yahoo
Arcturus Therapeutics Highlights mRNA Pipeline, CF Data and Vaccine Expansion at Jefferies
2026-06-05 09:02 · Yahoo
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation
2026-09-28 13:57 · Yahoo
CoreWeave upgraded, Etsy downgraded: Wall Street's top analyst calls
2026-09-24 13:41 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.